Vyome Holdings, Inc. Cash Flow Conversion Efficiency
Vyome Holdings, Inc. cash flow conversion efficiency. Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has a cash flow conversion efficiency ratio of -0.124x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-903.71K) by net assets ($7.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vyome Holdings, Inc. (2005–2025)
Cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2025. This chart illustrates how Vyome Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View HIND share price today for real-time trading data and today's change.
Vyome Holdings, Inc. Cash Flow Conversion Ratio Explained
Vyome Holdings, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vyome Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyome Holdings, Inc. ranked by their cash flow conversion efficiency. Also see Vyome Holdings, Inc. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tellusgruppen AB
ST:TELLUS
|
0.738x |
|
Telefast Indonesia
JK:TFAS
|
0.023x |
|
Playtech Plc
LSE:PTEC
|
-0.001x |
|
Avillion Bhd
KLSE:8885
|
-0.004x |
|
TRIBECA RESOURCES CORPORA
F:381
|
N/A |
|
Cannabist Company Holdings Inc
NEO:CBST
|
0.161x |
|
Metal Energy Corp
V:MERG
|
0.042x |
|
GMV Minerals Inc
V:GMV
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Vyome Holdings, Inc. (2005–2025)
The table below shows the annual cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2025. Review Vyome Holdings, Inc. (HIND) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.76 Million | $-3.75 Million | -0.997x | -105.69% |
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1625.07% |
| 2021-12-31 | $44.33 Million | $-15.38 Million | -0.347x | +41.23% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.19% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.16% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more